BioCentury | Nov 1, 2019
Product Development

Novartis, Merck KGaA see opportunity in select pockets of MS patients

As companies continue to pile into the multiple sclerosis market with new therapies, Novartis and Merck KGaA are dissecting the landscape to define populations for their newly launched drugs. While the former is staking out...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

An analysis by the Institute for Clinical and Economic Review of price increases for some of the costliest drugs in the U.S. has found that seven of nine were not supported by new clinical evidence,...
BC Extra | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Mar 30, 2018
Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

Researchers at Northwestern University and colleagues reported data from a Phase III trial in 110 patients with highly active relapsing-remitting multiple sclerosis (MS) showing that conditioning with cyclophosphamide and rabbit anti-thymocyte globulin followed by non-myeloablative...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Extra | Jan 3, 2018
Company News

Allergan among companies unveiling price hikes

Allergan plc (NYSE:AGN) raised the price of 18 drugs by 9.5%, just under the company's pledge to limit yearly price increases to single digits, according to a Jefferies report. Allergan spokesperson Mark Marmur told BioCentury...
BC Week In Review | Dec 8, 2017
Company News

Biogen agrees to outcomes-based contract for MS portfolio

Biogen Inc. (NASDAQ:BIIB) signed an outcomes-based contract with PBM Prime Therapeutics LLC (Eagan, Minn.) for Biogen's multiple sclerosis drugs under Prime's CareCentered Contract program. Prime VP of Pharmaceutical Trade Relations Susan Scheid told BioCentury the...
BC Extra | Dec 1, 2017
Company News

Biogen agrees to outcomes-based contract for MS portfolio

Biogen Inc. (NASDAQ:BIIB) signed an outcomes-based contract with PBM Prime Therapeutics LLC for Biogen's multiple sclerosis drugs under Prime's CareCentered Contract program. Prime Therapeutics VP of Pharmaceutical Trade Relations Susan Scheid told BioCentury the contract...
BC Week In Review | Nov 10, 2017
Clinical News

Novartis reports final Phase III data of Gilenya in pediatric MS

Novartis AG (NYSE:NVS; SIX:NOVN) reported final data from the Phase III PARADIGMS trial in 215 patients ages 10-17 with multiple sclerosis showing that once-daily oral Gilenya (Imusera) fingolimod (FTY720) reduced annualized relapse rate (ARR) over...
Items per page:
1 - 10 of 646